{'52WeekChange': 0.081424,
 'SandP52WeekChange': None,
 'address1': '421 Kipling Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 31.09,
 'askSize': 900,
 'averageDailyVolume10Day': 439000,
 'averageVolume': 686031,
 'averageVolume10days': 439000,
 'beta': None,
 'beta3Year': None,
 'bid': 29.01,
 'bidSize': 2200,
 'bookValue': 3.918,
 'category': None,
 'circulatingSupply': None,
 'city': 'Palo Alto',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 31,
 'dayLow': 29.81,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': 81.611,
 'enterpriseValue': 3310150144,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 30.976715,
 'fiftyTwoWeekHigh': 48.36,
 'fiftyTwoWeekLow': 14.23,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 42695536,
 'forwardEps': -2.36,
 'forwardPE': -12.817797,
 'fromCurrency': None,
 'fullTimeEmployees': 296,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.12478,
 'heldPercentInstitutions': 0.96074,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/bridgebio.com',
 'longBusinessSummary': 'BridgeBio Pharma, Inc. engages in the discovery, '
                        'development, and delivery of various medicines for '
                        'genetic diseases. The company has a pipeline of 20 '
                        'development programs that include product candidates '
                        'ranging from early discovery to late-stage '
                        'development. Its products in development programs '
                        'include BBP-265, an oral small molecule transthyretin '
                        '(TTR), which is ongoing Phase 3 clinical trial for '
                        'the treatment of TTR amyloidosis, including '
                        'cardiomyopathy and polyneuropathy manifestations; '
                        'infigratinib, an oral FGFR1-3 selective tyrosine '
                        'kinase inhibitor for the treatment of FGFR-driven '
                        'cancers and achondroplasia; BBP-631, a preclinical '
                        'adeno-associated virus gene transfer product '
                        'candidate for the treatment of congenital adrenal '
                        'hyperplasia caused by 21OHD; and BBP-454, a '
                        'preclinical development program for small molecule '
                        'inhibitors of KRAS for the treatment of pan-mutant '
                        'KRAS-driven cancers. The company also engages in '
                        'developing products for Mendelian, genetic '
                        'dermatology, oncology, and gene therapy diseases. '
                        'BridgeBio Pharma, Inc. has license agreements with '
                        'the Leland Stanford Junior University, The Regents of '
                        'the University of California, and Leidos Biomedical '
                        'Research, Inc.; and strategic collaboration '
                        'agreements with Johns Hopkins University and '
                        'University of Florida. The company was founded in '
                        '2015 and is headquartered in Palo Alto, California.',
 'longName': 'BridgeBio Pharma, Inc.',
 'market': 'us_market',
 'marketCap': 3671442432,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_412911458',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -291252000,
 'nextFiscalYearEnd': 1640908800,
 'open': 30.45,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650-391-9740',
 'previousClose': 30.68,
 'priceHint': 2,
 'priceToBook': 7.720776,
 'priceToSalesTrailing12Months': 90.5188,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 31,
 'regularMarketDayLow': 29.81,
 'regularMarketOpen': 30.45,
 'regularMarketPreviousClose': 30.68,
 'regularMarketPrice': 30.45,
 'regularMarketVolume': 297068,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 121370000,
 'sharesPercentSharesOut': 0.093,
 'sharesShort': 11288605,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8903322,
 'shortName': 'BridgeBio Pharma, Inc.',
 'shortPercentOfFloat': 0.22479999,
 'shortRatio': 12.12,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'BBIO',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.729,
 'twoHundredDayAverage': 30.652914,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'd3adccf0-6693-305c-9651-8da79033d61c',
 'volume': 297068,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://bridgebio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94301'}